Catabasis Pharmaceuticals (CATB) announced that its Phase 3 PolarisDMD trial of edasalonexent for Duchenne muscular dystrophy did not meet the primary endpoint, indicating no significant change in the North Star Ambulatory Assessment compared to placebo. Secondary endpoints also failed to demonstrate meaningful improvements. Despite this, edasalonexent was generally safe and well-tolerated. The company is halting the development of edasalonexent and will explore strategic options. As of September 30, 2020, Catabasis reported cash equivalents of approximately $52.9 million.
Catabasis Pharmaceuticals (NASDAQ:CATB) presented new findings on edasalonexent at the 25th International Congress of the World Muscle Society. The Phase 3 program for Duchenne muscular dystrophy (DMD) showcases promising preclinical data indicating benefits for cardiac function and bone health in mouse models. The upcoming PolarisDMD trial's top-line results are anticipated in Q4 2020. Initial patient assessments indicated stability in physical function measurements. Edasalonexent has orphan drug and fast track designations from the FDA, underscoring its potential as a foundational therapy for DMD.